Not checked for notices yet.
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Dan Liu, Jun Zhou, Yongsheng Wang and 21 more
BMC Medicine · 2022
doi:10.1186/s12916-022-02605-9
Cited by papers we hold 3
- Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer · 2025No notice
- Targeting cytokine and chemokine signaling pathways for cancer therapy · 2024No notice
- Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy · 2024No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.